A Phase 3 interventional study of SOF and RBV in Hepatitis C, sponsored by Gilead Sciences. Completed at 78 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-20.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies testing sofosbuvir in Hepatitis C — 1 open to participants now, 3 under way, none of them phase 3. Sofosbuvir · Hepatitis C.
Among the 94 studies testing sofosbuvir in Hepatitis C, this one is the 6th largest by enrollment, is one of 7 that started in 2013, is one of 30 in phase 3, and was the 21st registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →1 of the 94 studies testing sofosbuvir in Hepatitis C is open now. Recruiting first, the newest first:
Eastern Idaho Public Health
Ages 18+
Sofosbuvir: first FDA approval 2013 (SOVALDI), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 34 · Phase 3 31 · Phase 4 22
First in 2010; this study’s year is marked. 7 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 601 is above the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 75 across the 94 interventional studies. Of the 78 that completed or were terminated, 50 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 94 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
110 studies in Hepatitis C by Gilead Sciences: none open now, none under way, none of them phase 3. Of 109 finished, 79 (72%) have results posted.
Among the 110 studies in Hepatitis C by Gilead Sciences, this one is the 5th largest by enrollment of the 97 interventional ones that give a count, is one of 14 that started in 2013, is one of 35 in phase 3, and was the 47th registered.
Gilead Sciences’s Hepatitis C studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 94 studies testing sofosbuvir in Hepatitis C, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 110 in Hepatitis C:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess the efficacy, safety, and tolerability of 16 or 24 weeks of sofosbuvir (Sovaldi®; SOF) + ribavirin (RBV), and 12 weeks of SOF+RBV+ pegylated interferon (Peg-IFN) in treatment-naive and treatment-experienced adults with chronic genotype 3 hepatitis C virus (HCV) infection, and treatment-experienced adults with cirrhosis and chronic genotype 2 HCV infection.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SOF+RBV for 16 weeks
Drug: SOF · Drug: RBV
SOF+RBV for 24 weeks
Drug: SOF · Drug: RBV
SOF+RBV+Peg-IFN for 12 weeks
Drug: SOF · Drug: RBV · Drug: Peg-IFN
Participants from the SOF+RBV arms (16 weeks or 24 weeks) who experienced virologic failure on treatment, or during the posttreatment period at or before Posttreatment Week 24 may be eligible to enroll into the Retreatment Substudy to receive SOF+RBV+Peg-IFN for 12 weeks.
Drug: SOF · Drug: RBV · Drug: Peg-IFN
400 mg tablet administered orally once daily
Also known as: Sovaldi®, GS-7977, PSI-7977
Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
180 µg administered via subcutaneous injection once weekly
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.
Time frame: Posttreatment Week 12
Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
Time frame: Up to 24 weeks
Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
SVR4 and SVR 24 were defined as HCV RNA \< LLOQ at 4 and 24 weeks after stopping study treatment, respectively.
Time frame: Posttreatment Weeks 4 and 24
Percentage of Participants With HCV RNA < LLOQ at Weeks 1, 2, 4, 8, 12, 16, 20, and 24
Time frame: Weeks 1, 2, 4, 8, 12, 16, 20, and 24
HCV RNA at Weeks 1, 2, 4, 8, and 12
Time frame: Weeks 1, 2, 4, 8, and 12
Change From Baseline in HCV RNA at Weeks 1, 2, 4, 8, and 12
Time frame: Baseline; Weeks 1, 2, 4, 8, and 12
Percentage of Participants Experiencing On-Treatment Virologic Failure
On-treatment virologic failure was defined as: * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment), or * Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)
Time frame: Up to 24 weeks
Percentage of Participants Experiencing Viral Relapse
Viral relapse is defined as HCV RNA ≥ LLOQ during the post-treatment period having achieved HCV RNA \< LLOQ at end of treatment, confirmed with 2 consecutive values or last available post-treatment measurement.
Time frame: Up to Posttreatment Week 24
Participants were enrolled at study sites in Europe, North America, Australia, and New Zealand. The first participant was screened on 24 September 2013. The last study visit occurred on 07 July 2016.
| Milestone | SOF+RBV 16 Weeks, Then Retreatment | SOF+RBV 24 Weeks, Then Retreatment | SOF+RBV+Peg-IFN 12 Weeks |
|---|---|---|---|
| Started | 200 | 201 | 200 |
| Completed | 190 | 190 | 189 |
| Not completed | 10 | 11 | 11 |
| Withdrew: Randomized but never treated | 4 | 2 | 3 |
| Withdrew: Lost to follow-up | 2 | 4 | 4 |
| Withdrew: Withdrew consent | 3 | 3 | 2 |
| Withdrew: Adverse event | 1 | 1 | 0 |
| Withdrew: Death | 0 | 0 | 2 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
| Milestone | SOF+RBV 16 Weeks, Then Retreatment | SOF+RBV 24 Weeks, Then Retreatment | SOF+RBV+Peg-IFN 12 Weeks |
|---|---|---|---|
| Started | 20 | 10 | 0 |
| Completed | 18 | 10 | 0 |
| Not completed | 2 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.
| percentage of participants | SOF+RBV 16 Weeks | SOF+RBV 24 Weeks | SOF+RBV+Peg-IFN 12 Weeks |
|---|---|---|---|
| Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) | 71.9 | 85.4 | 92.9 |
| percentage of participants | SOF+RBV 16 Weeks | SOF+RBV 24 Weeks | SOF+RBV+Peg-IFN 12 Weeks |
|---|---|---|---|
| Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event | 1.5 | 1.5 | 1.5 |
SVR4 and SVR 24 were defined as HCV RNA \< LLOQ at 4 and 24 weeks after stopping study treatment, respectively.
| percentage of participants | SOF+RBV 16 Weeks | SOF+RBV 24 Weeks | SOF+RBV+Peg-IFN 12 Weeks |
|---|---|---|---|
| SVR4 | 73.0 | 85.9 | 95.9 |
| SVR24 | 71.9 | 84.4 | 93.4 |
| percentage of participants | SOF+RBV 16 Weeks | SOF+RBV 24 Weeks | SOF+RBV+Peg-IFN 12 Weeks |
|---|---|---|---|
| Week 1 | 14.8 | 20.1 | 25.9 |
| Week 2 | 53.3 | 53.5 | 67.0 |
| Week 4 | 86.6 | 91.9 | 97.4 |
| Week 8 | 99.5 | 99.5 | 99.5 |
| Week 12 | 100.0 | 98.5 | 100.0 |
| Week 16 | 99.0 | 99.5 | — |
| Week 20 | — | 99.5 | — |
| Week 24 | — | 100.0 | — |
| log10 IU/mL | SOF+RBV 16 Weeks | SOF+RBV 24 Weeks | SOF+RBV+Peg-IFN 12 Weeks |
|---|---|---|---|
| Week 1 | 2.13 ± 0.658 | 2.08 ± 0.749 | 1.81 ± 0.576 |
| Week 2 | 1.44 ± 0.436 | 1.45 ± 0.487 | 1.32 ± 0.342 |
| Week 4 | 1.19 ± 0.156 | 1.21 ± 0.287 | 1.16 ± 0.085 |
| Week 8 | 1.15 ± 0.021 | 1.15 ± 0.100 | 1.15 ± 0.000 |
| Week 12 | 1.15 ± 0.000 | 1.17 ± 0.318 | 1.15 ± 0.000 |
| log10 IU/mL | SOF+RBV 16 Weeks | SOF+RBV 24 Weeks | SOF+RBV+Peg-IFN 12 Weeks |
|---|---|---|---|
| Week 1 | -4.18 ± 0.559 | -4.15 ± 0.664 | -4.46 ± 0.556 |
| Week 2 | -4.86 ± 0.661 | -4.78 ± 0.714 | -4.96 ± 0.661 |
| Week 4 | -5.11 ± 0.671 | -5.02 ± 0.735 | -5.12 ± 0.699 |
| Week 8 | -5.16 ± 0.684 | -5.08 ± 0.708 | -5.12 ± 0.691 |
| Week 12 | -5.15 ± 0.686 | -5.05 ± 0.788 | -5.12 ± 0.691 |
On-treatment virologic failure was defined as: * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment), or * Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)
| percentage of participants | SOF+RBV 16 Weeks | SOF+RBV 24 Weeks | SOF+RBV+Peg-IFN 12 Weeks |
|---|---|---|---|
| Percentage of Participants Experiencing On-Treatment Virologic Failure | 0 | 1.5 | 0 |
Viral relapse is defined as HCV RNA ≥ LLOQ during the post-treatment period having achieved HCV RNA \< LLOQ at end of treatment, confirmed with 2 consecutive values or last available post-treatment measurement.
| percentage of participants | SOF+RBV 16 Weeks | SOF+RBV 24 Weeks | SOF+RBV+Peg-IFN 12 Weeks |
|---|---|---|---|
| Percentage of Participants Experiencing Viral Relapse | 26.7 | 12.3 | 4.6 |
Collected over Up to 24 weeks plus 30 days (Randomized Period) Up to 12 additional weeks plus 30 days (Retreatment Period). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Randomized Period: SOF+RBV 16 Weeks | 0/196 (0%) | 8/196 (4.1%) | 173/196 (88.3%) |
| Randomized Period: SOF+RBV 24 Weeks | 0/199 (0%) | 10/199 (5%) | 176/199 (88.4%) |
| Randomized Period: SOF+RBV+Peg-IFN 12 Weeks | 0/197 (0%) | 12/197 (6.1%) | 192/197 (97.5%) |
| Retreatment Period: SOF+RBV+Peg-IFN 12 Weeks | 0/30 (0%) | 1/30 (3.3%) | 29/30 (96.7%) |
| Event | Randomized Period: SOF+RBV 16 Weeks | Randomized Period: SOF+RBV 24 Weeks | Randomized Period: SOF+RBV+Peg-IFN 12 Weeks | Retreatment Period: SOF+RBV+Peg-IFN 12 Weeks |
|---|---|---|---|---|
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 0/196 | 0/199 | 0/197 | 1/30 |
| Acute coronary syndromeCardiac disorders | 1/196 | 0/199 | 0/197 | 0/30 |
| PancreatitisGastrointestinal disorders | 1/196 | 1/199 | 0/197 | 0/30 |
| Chest painGeneral disorders | 1/196 | 0/199 | 0/197 | 0/30 |
| CellulitisInfections and infestations | 1/196 | 0/199 | 0/197 | 0/30 |
| ArthritisMusculoskeletal and connective tissue disorders | 1/196 | 0/199 | 0/197 | 0/30 |
| Adenocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/196 | 0/199 | 0/197 | 0/30 |
| DepressionPsychiatric disorders | 1/196 | 0/199 | 1/197 | 0/30 |
| Suicidal ideationPsychiatric disorders | 1/196 | 0/199 | 0/197 | 0/30 |
| Orthostatic hypotensionVascular disorders | 1/196 | 0/199 | 0/197 | 0/30 |
| Event | Randomized Period: SOF+RBV 16 Weeks | Randomized Period: SOF+RBV 24 Weeks | Randomized Period: SOF+RBV+Peg-IFN 12 Weeks | Retreatment Period: SOF+RBV+Peg-IFN 12 Weeks |
|---|---|---|---|---|
| FatigueGeneral disorders | 74/196 | 83/199 | 92/197 | 18/30 |
| HeadacheNervous system disorders | 61/196 | 72/199 | 70/197 | 12/30 |
| InsomniaPsychiatric disorders | 47/196 | 56/199 | 50/197 | 2/30 |
| NauseaGastrointestinal disorders | 32/196 | 34/199 | 50/197 | 7/30 |
| MyalgiaMusculoskeletal and connective tissue disorders | 12/196 | 19/199 | 33/197 | 7/30 |
| Influenza like illnessGeneral disorders | 7/196 | 8/199 | 39/197 | 6/30 |
| PyrexiaGeneral disorders | 5/196 | 7/199 | 29/197 | 6/30 |
| PruritusSkin and subcutaneous tissue disorders | 21/196 | 24/199 | 22/197 | 6/30 |
| RashSkin and subcutaneous tissue disorders | 24/196 | 27/199 | 39/197 | 6/30 |
| Decreased appetiteMetabolism and nutrition disorders | 13/196 | 16/199 | 35/197 | 3/30 |
Safety Analysis Set: participants with genotype 2 or 3 HCV infection who were randomized and received at least 1 dose of study drug.
| Age, Continuous(years) | SOF+RBV 16 Weeks | SOF+RBV 24 Weeks | SOF+RBV+Peg-IFN 12 Weeks | Total |
|---|---|---|---|---|
| Mean | 51 ± 9.7 | 49 ± 9.8 | 50 ± 10.2 | 50 ± 9.9 |
| Sex: Female, Male(Participants) | SOF+RBV 16 Weeks | SOF+RBV 24 Weeks | SOF+RBV+Peg-IFN 12 Weeks | Total |
|---|---|---|---|---|
| Female | 62 | 70 | 65 | 197 |
| Male | 134 | 129 | 132 | 395 |
| Race/Ethnicity, Customized(participants) | SOF+RBV 16 Weeks | SOF+RBV 24 Weeks | SOF+RBV+Peg-IFN 12 Weeks | Total |
|---|---|---|---|---|
| Hispanic or Latino | 5 | 5 | 2 | 12 |
| Not Hispanic or Latino | 188 | 188 | 191 | 567 |
| Not Disclosed | 3 | 6 | 4 | 13 |
| Race/Ethnicity, Customized(participants) | SOF+RBV 16 Weeks | SOF+RBV 24 Weeks | SOF+RBV+Peg-IFN 12 Weeks | Total |
|---|---|---|---|---|
| Black or African American | 2 | 2 | 2 | 6 |
| White | 162 | 168 | 165 | 495 |
| Asian | 29 | 26 | 25 | 80 |
| American Indian/ Alaska Native/ First Nations | 2 | 0 | 0 | 2 |
| Hawaiian or Pacific Islander | 0 | 1 | 2 | 3 |
| Other | 0 | 1 | 1 | 2 |
| Not Disclosed | 1 | 1 | 2 | 4 |
| Region of Enrollment(participants) | SOF+RBV 16 Weeks | SOF+RBV 24 Weeks | SOF+RBV+Peg-IFN 12 Weeks | Total |
|---|---|---|---|---|
| New Zealand | 15 | 12 | 13 | 40 |
| Canada | 21 | 33 | 29 | 83 |
| United States | 29 | 33 | 31 | 93 |
| United Kingdom | 86 | 82 | 80 | 248 |
| Australia | 45 | 39 | 44 | 128 |
| HCV Genotype(participants) | SOF+RBV 16 Weeks | SOF+RBV 24 Weeks | SOF+RBV+Peg-IFN 12 Weeks | Total |
|---|---|---|---|---|
| Genotype 2 | 15 | 17 | 16 | 48 |
| Genotype 3 | 181 | 182 | 181 | 544 |
| IL28b Status(participants) | SOF+RBV 16 Weeks | SOF+RBV 24 Weeks | SOF+RBV+Peg-IFN 12 Weeks | Total |
|---|---|---|---|---|
| CC | 75 | 73 | 78 | 226 |
| CT | 94 | 95 | 98 | 287 |
| TT | 27 | 31 | 21 | 79 |
| HCV RNA(log10 IU/mL) | SOF+RBV 16 Weeks | SOF+RBV 24 Weeks | SOF+RBV+Peg-IFN 12 Weeks | Total |
|---|---|---|---|---|
| Mean | 6.3 ± 0.68 | 6.2 ± 0.71 | 6.3 ± 0.69 | 6.3 ± 0.69 |
1 further baseline measures are reported on the registry.
Ran from Sep 2013 to primary completion in Jan 2015, 15 months.
Results were first posted in Feb 2016, 1 year after primary completion.
Of 68 industry-sponsored phase 3 interventional studies under Hepatitis C, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 18. This study's 15 months is above that.
Counting every sponsor, half of 90 studies reached it within 14 months; a quarter within 10 and three quarters within 22.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sofosbuvir · Ribavirin